News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>JPM Favors AKESO/ INNOVENT BIO/ HENGRUI PHARMA as CN Healthcare Sector Rebounds Sharply This Yr
China's healthcare sector has experienced a sharp rebound YTD, with the MSCI China Health Care Index surging by around 50%, according to JPMorgan's research report.In JPMor...
Reset
Send
The window will close in 5 seconds
<Research>JPM Favors AKESO/ INNOVENT BIO/ HENGRUI PHARMA as CN Healthcare Sector Rebounds Sharply This Yr
Close
Recommend
13
Positive
20
Negative
7
 
SHORT SELL
 
STOCK INFO

China's healthcare sector has experienced a sharp rebound YTD, with the MSCI China Health Care Index surging by around 50%, according to JPMorgan's research report.

In JPMorgan's estimate, the Hang Seng Healthcare Index (HSHCI) could reach or even exceed its 2022/23 highs, namely around 4,400-4,600.

Related NewsBOCOMI Ratings, TPs on CN Pharma Stocks (Table)
As the strong momentum may persist in the short term, JPMorgan believes that stocks with upcoming catalysts are well-positioned to continue outpacing the market. The broker preferred AKESO (09926.HK)  +1.200 (+0.860%)    Short selling $152.59M; Ratio 10.551%   , INNOVENT BIO (01801.HK)  -0.050 (-0.056%)    Short selling $169.87M; Ratio 12.225%   , and HENGRUI PHARMA (01276.HK)  +1.300 (+1.813%)   , while those with fewer catalysts included SKB BIO-B (06990.HK)  +4.200 (+1.093%)    Short selling $12.00M; Ratio 4.016%   , REMEGEN (09995.HK)  +1.800 (+2.611%)    Short selling $13.20M; Ratio 1.449%   and JUNSHI BIO (01877.HK)  +0.100 (+0.398%)    Short selling $17.35M; Ratio 9.297%   .
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-07-18 16:25.)

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.